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Vitamin A has preventive effects on obesity. All-trans retinoic acid (ATRA), the active form of vita-
min A, inhibits lipid accumulation in 3T3-L1 cells in an experimental adipogenesis model. We found
that ATRA suppressed up-regulation of the amino acid transporter, Asct2, in adipogenerating 3T3-L1
cells. We observed that Asct2 was up-regulated at 1 day after adipogenesis stimuli. The Asct2 inhi-
bitor L-c-glutamyl-p-nitroanilide (GPNA) decreased lipid accumulation. Glutamine-free conditions
also suppressed adipogenesis. Suppression of adipogenesis by ATRA may be through Asct2 reduc-
tion. These results indicate that Asct2 could be a target for obesity prevention and treatment.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Obesity is the leading risk for the development of type 2 diabetes
mellitus, hypertension and cardiovascular disease. Experiments
have shown thatmolecularmechanisms of adipogenesis form a link
between obesity and insulin resistance [1]. Vitamin A is an
important nutrient that has multiple biological functions that affect
vision, embryonic development, reproduction, and immune
function [2–4]. The bioactive form of vitamin A is all-trans retinoic
acid (ATRA); a nutrient derivative with many remarkable effects on
adipocyte biology affecting preadipocyte survival, and adipogenesis
in preadipocyte clonal cell lines [5,6]. ATRA treatment reduces body
weight and adiposity [7,8]. ATRA is a speciﬁc ligand for retinoic
acid receptors (RARs), and in part, it suppresses adipogenesis
through activation of RARs. Several reports have indicated that
various adipogenic signaling pathways are involved in the
ATRA-dependent regulation of adipogenesis [6–12].The mouse preadipocyte cell line, 3T3-L1 provides a model for
differentiation process associated with adipogenesis, including
activation of the adipogenetic signaling pathway. The temporal
expression pattern of important adipogenic factors is regulated
by speciﬁc adipogenous transcription factors [13]. In particular,
peroxisome proliferator-activated receptor c (PPARc) is a tran-
scription factor that up-regulates adipocyte-speciﬁc genes
involved in lipid synthesis, and insulin signaling. It also regulates
adipokine production for terminal differentiation, and PPARc ago-
nists, including pioglitazone, promote 3T3-L1 cell differentiation to
mature adipocytes [14,15].
Asct2 (SLC1A5) is a neural amino acid transporter belonging to
the solute carrier 1 family. Asct2 is expressed in many tissues,
including placenta, lung, intestine and adipose-tissue [16,17].
Lane et al. have shown that Asct2 expression is activated by
insulin-treatment [17]. Since Asct2 shows high afﬁnity toward glu-
tamine, Asct2 is essential for glutamine uptake in growing epithe-
lial cells [18]. Bungard and McGivan have shown that Asct2
expression is regulated by farnesoid X Receptor (FXR)/retinoid X
receptor (RXR) heterodimers in hepatoma cell line HepG2 cells
[19,20]. Recently Palmada et al. have reported that Asct2 activity
is regulated by serine-threonine kinases stimulated by insulin
and insulin-like growth factor (IGF) [21]. We hypothesized that
Asct2 in adipocytes may represent a new anti-obesity target.
When using differentiating 3T3-L1 cells as an experimental adi-
pogenesis model, bio-synthesis of triacylglycerol, which is made
from glucose and amino acids, is accelerated, resulting in enlarged
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Asct2 expression in these cells. In addition, we found in 3T3-L1
cells that the speciﬁc Asct2 inhibitor, L-c-glutamyl-p-nitroanilide
(GPNA) [22], inhibits adipogenesis in an additive fashion with
ATRA. While GPNA has little effect on the expression levels of asct2
and glut4, GPNA decreases the protein levels of PPARc. We hypoth-
esized that inhibition of Asct2 may prevent obesity by suppression
of glutamine-uptake. Inhibition of Asct2 by daily vitamin A intake
may be sufﬁcient to reduce obesity.
2. Materials and method
2.1. Cell culture
Murine preadipocyte, 3T3-L1 cells (obtained from Dr. Fumio
Fukai, Department of Pharmaceutical Sciences, Tokyo University
of Science), were routinely cultured in growth medium consisting
of DMEM (Wako Pure Chemical Industries, Ltd., Tokyo, Japan) sup-
plemented with 10% heat-inactivated FBS (Invitrogen, Carlsbad, CA,
USA), 2 mM glutamine, 100 units/ml penicillin, and 100 units/ml
streptomycin in 5% CO2 incubator at 37 C. For glutamine free con-
ditions, DMEM high glucose without glutamine (Wako) was sup-
plemented with 10% heat-inactivated FBS, 100 units/ml penicillin,
and 100 units/ml streptomycin.
2.2. Adipocyte differentiation
Routinely cultured 3T3-L1 cells were differentiated according to
an established protocol [23]. Brieﬂy, cells were cultured to full
conﬂuence. At 2 days post conﬂuence (referred to as day 0), cells
were stimulated with induction medium consisting of growth
medium with DIM (1 lM dexamethasone, 0.5 mM isobutyl-
methylxanthine, and 1 lg/ml insulin). After 20 h, cells were
switched to ‘‘insulin medium’’, consisting of growth medium
with 1 lg/ml insulin, and were maintained for 7 days. The cells
normally differentiated into mature adipocytes on day 7. For
examining the effects on adipogenesis of ATRA (Sigma, St. Louis,
USA) and L-c-glutamyl-p-nitroanilide (GPNA, Wako), compounds
were added to the insulin medium.
2.3. Oil Red-O staining
To evaluate the extent of lipid accumulation in DIM-stimulated
3T3-L1 cells, the oil Red-O staining method was utilized as previ-
ously reported [23]. In brief, cells were ﬁxed with 10% formalin
at room temperature, and were then washed with PBS and 60% iso-
propyl alcohol, followed by treatment with oil Red-O (2.1 mg/ml
60% isopropyl alcohol) at room temperature. Cells were then
washed in turn with 60% isopropyl alcohol and PBS. To perform
quantitative measurement of the accumulated lipids, the oil
Red-O stained wells were treated with 100% isopropyl alcohol to
extract oil Red-O, and the solutions were then measured for absor-
bance at 510 nm.
2.4. Immunoblotting analysis
Whole cell lysates were prepared with NP40 lysis buffer [23,24].
The protein concentration of the whole cell lysates was determined
by the Bicinchoninic Acid (BCA) Protein Assay (Piece, Rockford, IL,
USA). Whole lysates were subjected to SDS–polyacrylamide gel
electrophoresis (SDS–PAGE), and were transferred to
Immobilon-P membranes (Millipore, Billerica, MA, USA). The
membranes were probed with either polyclonal antibodies
against ASCT2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
PPARc (Cell Signaling, Danvers, MA, USA), or glyceraldehyde3-phosphate dehydrogenase (Gapdh, Abcam, Cambridge, MA,
USA). Proteins were visualized using ECL-plus (Invitrogen).
2.5. Quantitative RT-PCR
Total RNA of cultured 3T3-L1 cells was prepared with ISOGEN
reagent (Nippon gene, Toyama, Japan). Complementary DNA
(cDNA) of each tissue was prepared by reverse transcriptase (RT)
reactions from 1 lg total RNA using the Superscript First-Strand
Synthesis System for RT-PCR (Invitrogen). The sequences of the
PCR primers were as follows: asct2 (forward 50-GTC ACA GCC
ACA GCA TCC A-30, reverse 50-CCA GCC CCA AAA GCA TCA C-30), adi-
poq (forward 50-TGG CAG AGA TGG CAC TCC TG-30, reverse 50-GGT
CGT AGG TGA AGA GAA CG-30), pparg1 (forward 50-TGA AAG AAG
CGG TGA AC-30, reverse 50-TAG TGT GGA GCA GAA AT-30), pparg2
(forward 50-GCT GTT ATG GGT GAA AC-30, reverse 50-TAG TGT
GGA GCA GAA AT-30), b-actin (forward 50-AGC CAT GTA CGT AGC
CAT CC-30, reverse 50-ATT ACC GAG GAC GAG CCC AGA C-30).
Quantitative mRNA expression analysis was performed by a real
time PCR system (StepOneTM, Applied Biosystems Inc., Foster
City, CA, USA). To estimate the level of transcripts quantitatively,
b-actin transcript was used as an internal control for the each pre-
pared sample.
2.6. Confocal microscopic observation
Intracellular Asct2 localization was visualized by immunoﬂuo-
rescent staining with anti-ASCT2 antibodies (Cell Signaling).
In brief, harvested cells on 8-well chamber slides were treated
with DIM and ATRA as previously mentioned, and the cells were
ﬁxed with methanol. The ﬁxed cells were treated with
anti-ASCT2 antibodies, and subsequently immunostained with
Alexa546-conjugated anti-rabbit IgG antibody (Invitrogen).
Confocal microscopy was performed using an Olympus FV1200
instrument (Olympus, Tokyo, Japan).
2.7. Statistical analysis
All data were analyzed using Student’s t-test. Differences were
considered to be statistically signiﬁcant if the p-value was <0.001.3. Results
3.1. ATRA suppresses up-regulation of ASCT2 during adipogenesis
Several reports have shown that Asct2 transcripts are detected
in adipose tissues and that insulin up-regulates Asct2 expression in
adipogenesis-stimulated 3T3-L1 cells [16,17]. Since we hypothe-
sized that ATRA could potentially suppress 3T3-L1 adipogenesis
through Asct2 down-regulation, we added ATRA into the culture
medium of DIM-stimulated 3T3-L1 cells to examine the effects of
ATRA on the adipogenesis. The lipid droplets of the cultured cells
were stained with oil Red-O, and a quantitative estimation of the
accumulated lipid bodies was determined by measuring the oil
Red-O under each culture condition.
Inhibition of adipogenesis by ATRA was observed in a
dose-dependent manner. The quantity of lipid droplets decreased
by 63% with 1 nM, 30% with 10 nM, 15% with 100 nM, and by 2%
with 1 lM ATRA during adipogenesis, respectively (Fig. 1A). In
adipo-differentiating cells in vitro, the source of lipids is mainly
from glucose and amino acids in the culture medium. The neutral
amino acid transporter, Asct2, is an essential glutamine transporter
in proliferating cells. We found that, in DIM-stimulated 3T3-L1
cells, 1 lM ATRA treatment suppressed asct2 gene expression by
Fig. 1. Effects of ATRA on adipogenesis and Asct2 expression. (A) Lipid-droplets in the cultured 3T3-L1 cells detected with oil Red-O staining in insulin medium containing
various concentrations of ATRA after 7 days. Each bar represents the mean ± SD. (B) Expression levels of asct2 during adipocyte differentiation in 3T3-L1 cells treated with
0.1% ethanol (EtOH) and 0.1 lM ATRA (day 5) as revealed by quantitative RT-PCR. (C) Immunoblot detection of Asct2 and PPARc in 3T3-L1 cells treated with 0.1% EtOH and
1 lM ATRA (day 5). Gapdh was employed as an internal control. Graph shows the density of detected Asct2 normalized with Gapdh. The results are representative of three
independent experiments. (D) Immunoﬂuorescent staining of Asct2 in DIM-stimulated 3T3-L1 cells treated with 0.1% EtOH and 1 lM ATRA (day 5). Blue shows DAPI-stained
nuclei. Red shows immunostained Asct2. Arrows indicate the presence of Asct2 on the cell surface of DIM-stimulated 3T3-L1 cells during adipogenesis.
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asct2 genes increased until day 3, and then the levels decreased
in the late stage of adipogenesis (Supplementary Fig. 1). ASCT2
protein levels in the adipogenerating 3T3-L1 were suppressed by
54% following ATRA treatment (Fig. 1C). From immunoﬂuorescent
stain analysis, DIM-stimulated 3T3-L1 cells displayed Asct2 on
the surface of cells at 60 min following DIM-stimulation
(Supplementary Fig. 2A). DIM-stimulated cells treated with ATRA
had little Asct2 detection on cell surface (Fig. 1D). These results
indicate that ATRA may suppress expression and intracellular
localization of Asct2 during adipogenesis.
3.2. An Asct2 inhibitor suppresses adipogenesis of 3T3-L1 cells
Next, we examined the role of Asct2 in adipogenesis. To mea-
sure the contribution of Asct2 to adipogenesis, we used the Asct2
inhibitor, L-c-glutamyl-p-nitroanilide (GPNA) [22]. We performed
analysis by oil Red-O staining (Fig. 2), on DIM-stimulated 3T3-L1
cells following treatment with 500 lM GPNA, which is sufﬁcient
to achieve 100% inhibition of glutamine uptake [22]. We foundthat under these conditions, lipid accumulation was reduced by
approximately 12% during adipogenesis (Fig. 2A and B).
Treatment with 10 nM ATRA suppressed lipid accumulation by
34%, and co-treatment of 500 lM GPNA with 10 nM ATRA resulted
in 5% greater inhibitory effects on adipogenesis (Fig. 2A and B),
which equaled the effects of 1 lM ATRA (Fig. 1A and B). Based on
immunoﬂuorescent stain analysis, DIM-stimulated 3T3-L1 cells
treated with GPNA displayed the same level of Asct2 on the cell
surface as with ATRA treatment (Supplementary Fig. 2B). GPNA
suppressed adipogenesis in a dose-dependent manner
(Supplementary Fig. 3).
We investigated the effects of 500 lM GPNA on asct2 gene
expression. We found that GPNA addition down-regulated asct2
expression by 73% (Fig. 2C). GPNA also showed suppressive inﬂu-
ence on the expression levels of adipo-marker molecules at day
5, including adipoq and pparg2. This is consistent with the fact that
expression of adipoq genes is regulated by PPARc [25,26]. The sup-
pressive effects of GPNA were similar to those seen after treatment
with 1 lMATRA (Fig. 2C). GPNA reduced Asct2 and PPARc2 protein
levels in differentiating 3T3-L1 cells (Fig. 2D). The inhibition of
Fig. 2. Effects of the ASCT2 inhibitor GPNA on adipocyte-differentiation. (A) Lipid-droplets in the cultured 3T3-L1 cells detected with oil Red-O staining. Treatment
conditions: –DIM, +DIM, +DIM + 10 nM ATRA, +DIM + 10 nM ATRA + 500 lM GPNA, and +DIM + 500 lM GPNA. Cells were treated with compound(s) for 7 days. (B) Graphs of
relative levels of oil Red-O stained lipid-droplets in cultured 3T3-L1 cells. Relative intensities were standardized with +DIM. The results are representative of three
independent experiments. Each bar represents the mean ± SD. *p < 0.001 versus +DIM condition by Student’s t-test. (C) Expressions levels of asct2, adipoq and pparg in DIM-
stimulated 3T3-L1 cells treated with 500 lMGPNA or 0.1 lM ATRA for 5 days, as revealed by quantitative RT-PCR. (D) Immunoblotting analysis of Asct2 and PPARc in 3T3-L1
cells treated with 1 lM ATRA or 500 lM GPNA for 5 days. Gapdh was employed as an internal control. The density of detected Asct2 has been normalized with Gapdh. The
results are representative of three independent experiments.
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mulation by down-regulating Asct2 and PPARc2, which would be
reﬂected in reduced adipogenesis.
3.3. Early effects of ATRA and an Asct2 inhibitor on adipogenesis
We hypothesized that suppressing the action of ATRA might be
through decreasing Asct2 in DIM-stimulated 3T3-L1 cells. To iden-
tify the time course for this activity, we examined the lipid accu-
mulation in 3T3-L1 cells treated with 1 lM ATRA at various
intervals (Fig. 3A). At 3 day ATRA treatment, ATRA-treated cellsalready showed signiﬁcantly less lipid accumulation (53%) than
control cells (0.1% ethanol) (Fig. 3A). This implies that ATRA
affected adipogenesis of DIM-stimulated 3T3-L1 cells in early peri-
ods, when suppression of pparg up-regulation had not yet been
detected (Supplementary Fig. 1). We also investigated the time
course of lipid accumulation in GPNA-treated cells. We observed
that treatment with 500 lM GPNA enhanced lipid accumulation
until day 3, and showed further suppressive effects in later stages
(day 5 and 7) in a dose dependent manner (Fig. 3A). It is possible
that during the early stages of DIM-stimulation, Asct2 might be a
target of ATRA. Asct2 inhibition by GPNA might also suppress lipid
Fig. 3. Effects on adipogenesis of 3T3-L1 cells of treating with ATRA or GPNA for different time intervals. (A) Effect of ATRA and GPNA on lipid accumulation in DIM-
stimulated 3T3-L1 cells. Lipid droplets were stained with oil Red-O after 3 days, 5 days and 7 days of treatment with 1 lM ATRA or various concentrations of GPNA. Graphs
show the relative degree of staining. Relative intensities were standardized with 0.1% EtOH on day 3. *p < 0.001 versus control (0.1% EtOH) by Student’s t-test. (B, C), Alteration
of 500 lM GPNA treatment periods. (B) GPNA treatment schedules. (C) Graphs of relative levels of oil Red-O stained lipid-droplets in each condition. Relative intensities were
standardized with +DIM. Each bar represents the mean ± SD.
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shown that ATRA treatment was sufﬁcient to signiﬁcantly inhibit
adipogenesis at early stages as well as later periods [27].
Accordingly, we altered GPNA-treatment time points during adipo-
genesis (Fig. 3B and C). The initial 3 day treatment showed sup-
pressive effects on adipogenesis equal to the full treatment
(Fig. 3B and C). This data suggested that initial amino acid uptake
through Asct2 could be the primary source of the lipid droplets in
mature adipocytes. Since treatment with both ATRA and GPNA
indicated that adipogenesis-stimuli occurred in early stages
(3 days), uptake of amino acids including glutamine during thistime, might be indispensable for adipo-maturation and lipid dro-
plet formation.
3.4. Effects of glutamine free and GPNA treatment on 3T3-L1 cells
Asct2 is a neural amino acid transporter that has high afﬁnity
for glutamine. We examined the effects of GPNA treatment on adi-
pogenesis under glutamine free conditions. Under glutamine free
conditions, lipid accumulation decreased in differentiating
3T3-L1 cells by 31% (Fig. 4A, +DIM). Contrary to our expectations,
glutamine free conditions did not suppress adipogenesis as great
Fig. 4. Effects of glutamine free conditions on adipogenesis of 3T3-L1 cells. (A) Effect of L-glutamine (L-Gln)-free conditions and 500 lM GPNA on lipid accumulation in DIM-
stimulated 3T3-L1 cells at day 5. Open columns represent treatment with 5 mM L-Gln and closed columns represent the absence of L-Gln in culture media. Relative intensities
were standardized against +DIM + 5 mM L-Gln. Each bar represents the mean ± SD. Asterisk shows the statistical signiﬁcance between L-Gln-free conditions and 5 mM L-Gln
conditions (*p < 0.001). (B) Immunoblot detection of Asct2 and PPARc in 3T3-L1 cells treated with 500 lM GPNA for 5 days. Gapdh was used as internal control. Graph shows
the density of detected Asct2 normalized with Gapdh. The results are representative of three independent experiments.
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Glutamine free conditions increased PPARc levels in 3T3-L1 cells,
and suppressed reduction of Asct2 protein levels in the
DIM-treated cells (Fig. 4B). This data indicated that the degree of
lipid accumulation was not concomitant with Asct2 and PPARc
levels under glutamine free condition.
4. Discussion
In our current work, we have investigated ATRA’s suppressive
effects on adipogenesis of 3T3-L1 cells. We found that in the early
stages of adipogenesis ATRA down-regulated transcripts of asct2, a
neutral amino acid transporter. During adipogenesis, GPNA, an
Asct2 inhibitor, enhanced the suppressive activities of ATRA.
Treatment with GPNA at early time points during adipocyte differ-
entiation, was sufﬁcient to suppress adipogenesis at a level thatwas equal to full duration treatment with ATRA or GPNA. Our stud-
ies have revealed that Asct2 can effectively inhibit lipid accumula-
tion in preadipocytes.
ATRA has long been known to be an inhibitor of adipocyte dif-
ferentiation [6–12]. As shown in Fig. 3A, ATRA exhibits suppressive
effects from day 3 of treatment. Since the detectable activity in
early periods is concomitant with PPARc alteration, we hypothe-
sized a mechanism other than the nuclear receptor cascade.
Based on our results, it appears that Asct2 may be an ATRA target
for inhibiting adipogenesis. Asct2 is the primary amino acid trans-
porter for glutamine uptake, which serves as major source of tria-
cylglycerol. Accordingly, we anticipated that down-regulation of
asct2 could be an important component of ATRA’s inhibitory effects
on adipogenesis. In our current study, the inhibitory effects of
ATRA on Asct2 expression might not be dependent on FXR/RXR
(farnesoid X Receptor/retinoid X receptor). Rather these effects
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[28–30], RAR activation or inhibition of glutamine inﬂux. Kim
et al. have reported that soon after treatment with ATRA, adipoge-
nesis was signiﬁcantly inhibited. In ATRA treated cells,
Wnt/b-Catenin signaling components are up-regulated at 6 h after
adipogenesis stimulation [27]. To our knowledge, the relationship
between glutamine inﬂux and Wnt/b-Catenin signaling on adipo-
genesis has not been reported. However, Olkku and Mahonen have
indicated that the Wnt cascade inhibits intracellular glutamine
levels by regulating glutamine synthetase [31].
Rhoderick et al. have reported that among compounds synthe-
sized as Nc-Aryl glutamine analogues, the Asct2 inhibitor, GPNA,
had the most potent inhibitory effect on glutamine uptake [22].
Administration of GPNA to differentiating 3T3-L1 cells inhibits glu-
tamine uptake, resulting in decreased lipid synthesis. We exam-
ined the effects of varying the treatment duration with GPNA. At
early time points, GPNA suppressed adipogenesis of
DIM-stimulated 3T3-L1 cells (Fig. 3C). This result is similar to
Kim et al.’s results examining different time points of ATRA addi-
tion [27]. At the early time points, ATRA might inhibit adipogenesis
by suppressing uptake of glucose and amino acids. GPNA might
increase lipid accumulation up to day 3 by suppressing the uptake
of amino acids, but not glucose. We found that under
glutamine-free conditions, the formation of lipid droplets was
reduced (Fig. 4A). We hypothesized that glutamine free conditions
might achieve effects similar to treating differentiating 3T3-L1
cells with GPNA. Although GPNA reduced PPARc levels in differen-
tiating 3T3-L1 cells (Fig. 2C and D), we also found that reduction of
PPARc proteins might have occurred by mechanisms other than
those arising from glutamine free conditions (Fig. 4). This indicates
that glutamine is the major source for triacylglycerol. Therefore,
PPARc-upregulated 3T3-L1 cells are not able to intake insufﬁcient
glutamine to form lipid droplets under glutamine free conditions.
Accordingly, PPARc regulation and GPNA treatment are different
from glutamine-free conditions in 3T3-L1 cells. Under glutamine
free conditions, amino acids other than glutamine may be taken
up in preadipocytes in sufﬁcient quantities to maintain PPARc
levels, but not sufﬁcient for forming lipid droplets.
We found that treatment with GPNA had a suppressive effect
not only on the adipo-generating cells, but also on mature adipo-
cytes (Supplementary Fig. 4). Inhibition of Asct2 activities in
adipo-maturated 3T3-L1 cells might be effective against
lipid-accumulation. We had speculated that the GPNA might be
toxic to mature adipocytes, however the number of
GPNA-treated adipocytes (after 5 days) was not signiﬁcantly differ-
ent from the control-conditioned cultured cells. In contrast, ATRA
did not decrease accumulated lipids.
Our results suggest that targeting Asct2 activity could be a
means of preventing/treating obesity. Cooperation of vitamin A
(or ATRA) and an Asct2 inhibitor could potentially result in further
anti-obesity activity. Glutamine inﬂux might be a novel target for
the treatment/prevention of obesity.Conﬂicts of interest
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